Filtered By:
Condition: Atrial Fibrillation
Drug: Amiodarone

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 93 results found since Jan 2013.

Evaluation of early direct current cardioversion for maintenance of sinus rhythm in rheumatic atrial fibrillation following successful balloon mitral valvotomy.
CONCLUSION: In patients with rheumatic MS and AF, early DCCV and a short-duration oral Amiodarone, following successful PBMV, may be a reasonable strategy to attain long-term SR. PMID: 27543470 [PubMed - in process]
Source: Indian Heart J - June 30, 2016 Category: Cardiology Authors: Sharma G, Anantha Krishnan R, Bohra V, Ramakrishnan S, Naik N, Seth S, Juneja R, Kalaivani M, Bahl VK Tags: Indian Heart J Source Type: research

Management of New ‐Onset Postoperative Atrial Fibrillation Utilizing Insertable Cardiac Monitor Technology to Observe Recurrence of AF
Conclusion: POAF may represent a propensity for recurrent PAF, and not simply a transient consequence of post‐operative stress and inflammation. Better detection of recurrent AF might identify patients at risk for stroke who would benefit from continuing anticoagulation.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - July 31, 2016 Category: Cardiology Authors: MIKHAEL F. EL ‐CHAMI, FAISAL M MERCHANT, PAIGE SMITH, MATHEW LEVY, ANGELA GILL NELMS, JOHN MERLINO, JOHN PUSKAS, ANGEL R. LEON Tags: ELECTROPHYSIOLOGY Source Type: research

An uncommon tomographic association: amiodarone pulmonary toxicity and adenocarcinoma
ABSTRACT Obstructive sleep apnea (OSA) is a common clinical condition, with a variable and underestimated prevalence. OSA is the main condition associated with secondary systemic arterial hypertension, as well as with atrial fibrillation, stroke, and coronary artery disease, greatly increasing cardiovascular morbidity and mortality. Treatment with continuous positive airway pressure is not tolerated by all OSA patients and is often not suitable in cases of mild OSA. Hence, alternative methods to treat OSA and its cardiovascular consequences are needed. In OSA patients, regular physical exercise has beneficial effects other...
Source: Jornal Brasileiro de Pneumologia - January 9, 2017 Category: Respiratory Medicine Source Type: research

Management strategies for atrial fibrillation.
Abstract Atrial fibrillation is the most prevalent cardiac arrhythmia, affecting 10% of those aged over 80 years. Despite multiple treatment options, it remains an independent prognostic marker of mortality due to its association with clinical sequelae, particularly cerebrovascular events. Management can be broadly divided into treatment of the arrhythmia, via rhythm or rate control, and stroke thromboprophylaxis via anticoagulation. Traditional options for pharmacotherapy include negatively chronotropic drugs such as β-blockers, and/or arrhythmia-modifying drugs such as amiodarone. More recently, catheter ablati...
Source: J R Soc Med AND (has... - December 31, 2016 Category: Journals (General) Authors: Patel PA, Ali N, Hogarth A, Tayebjee MH Tags: J R Soc Med Source Type: research

Pulmonary embolism four days after interruption of therapy with rivaroxaban.
We report on a 58-year-old male with paroxysmal atrial fibrillation (AF) with a CHA2DS2VASC score of 4 who developed central pulmonary embolism four days after interruption of rivaroxaban because of parotid surgery. He had received 40 mg enoxaparin/d. The parotid gland was partially resected within 6 hours without blood loss. Pulmonary embolism and AF occurred on the first postoperative day. He recovered with low-molecular-weight heparin in therapeutic dosages and amiodarone and was discharged with phenprocoumon. The relevance of a rivaroxaban rebound phenomenon, manifesting as arterial embolism, stroke or venous thrombo...
Source: Hamostaseologie - August 24, 2017 Category: Hematology Authors: Stöllberger C, Göndör G Tags: Hamostaseologie Source Type: research

Management of amiodarone extravasation with intradermal hyaluronidase.
CONCLUSION: Administration of intradermal hyaluronidase after amiodarone extravasation was associated with decreased expansion of erythema and warmth as well as an improvement in patient-reported pain scores without any noted adverse effects. PMID: 28947526 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - September 29, 2017 Category: Drugs & Pharmacology Authors: Fox AN, Villanueva R, Miller JL Tags: Am J Health Syst Pharm Source Type: research

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
Kuan-Cheng Lai, Sy-Jou Chen, Chin-Sheng Lin, Fu-Chi Yang, Cheng-Li Lin, Chin-Wang Hsu, Wen-Chen Huang, Chia-Hung Kao
Source: Frontiers in Pharmacology - May 7, 2018 Category: Drugs & Pharmacology Source Type: research

Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients
ConclusionA significant number of patients received NOACs at doses inconsistent with the package labeling or had clinically significant drug –drug interactions with NOACs. Efforts are warranted to improve appropriate dosing and avoid significant drug interactions.
Source: American Journal of Cardiovascular Drugs - November 8, 2018 Category: Cardiology Source Type: research

Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
CONCLUSIONS: NOACs were equivalent to warfarin among AF patients with concomitant amiodarone use in terms of efficacy, safety, and mortality. There was no safety benefit of NOACs over warfarin in patients using polypharmacy or P-glycoprotein inhibitors. SYSTEMATIC REVIEW REGISTRATION: The protocol of this meta-analysis was registered on PROSPERO under CRD42018104808 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42018104808). PMID: 30770140 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 12, 2019 Category: Cardiology Authors: Kim IS, Kim HJ, Yu HT, Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, Pak HN Tags: J Cardiol Source Type: research

The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding
AbstractThe use of direct oral anticoagulants for stroke prevention in atrial fibrillation continues to rise. Certain populations may be at higher risk for increased drug exposure and adverse events. Pharmacokinetic studies suggest increased exposure of rivaroxaban and apixaban with combined P-gp and moderate CYP3A4 inhibitors but the clinical relevance of this is unknown. This retrospective cohort study included patients receiving rivaroxaban or apixaban from January 1, 2012 to December 31, 2016 with a moderate inhibitor (amiodarone, dronedarone, diltiazem, verapamil) for at least 3 months in the drug –drug interaction ...
Source: Journal of Thrombosis and Thrombolysis - January 9, 2020 Category: Hematology Source Type: research

Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care
In this study, we assessed the impact of interacting medication and pharmacogenetic variation to better explain apixaban concentration differences among 358 Caucasian AF patients. Genotyping (ABCG2,ABCB1,CYP3A4*22,CYP3A5*3) was performed by TaqMan assays, and apixaban quantified by mass spectrometry. The typical patient was on average 77.2  years old, 85.5 kg, and had a serum creatinine of 103.1 µmol/L. Concomitant amiodarone, an antiarrhythmic agent and moderate CYP3A/ABCB1 inhibitor, the impaired-function variantABCG2 c.421C  >  A, and sex predicted higher apixaban concentrations when controlling for age, weig...
Source: Journal of Thrombosis and Thrombolysis - January 18, 2020 Category: Hematology Source Type: research

One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study.
CONCLUSIONS: The follow-up of the BLITZ-AF study provide an up to date picture of the clinical course of patients with AF, who appear frequently affected by heart failure and severe comorbidities which might have led to the high mortality rate. PMID: 31952984 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - January 13, 2020 Category: Internal Medicine Authors: Cemin R, Colivicchi F, Maggioni AP, Boriani G, De Luca L, Di Lenarda A, Di Pasquale G, Fabbri G, Lucci D, Gulizia MM, On the behalf of BLITZ-AF Investigators Tags: Eur J Intern Med Source Type: research

Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management
Hypertrophic cardiomyopathy (HCM) is 1 of the most frequent genetic cardiovascular diseases affecting 1 out of every 500 individuals in general population. Atrial Fibrillation incidences were 3.8% per 100 patients per year and overall prevalence among HCM patients are 27.09%. Higher risk of death noted in HCM patients with atrial fibrillation. Stroke and other thrombo embolic risks are increased in such patients. Medical management using mainly betablockers or amiodarone produced variable results and high rate of recurrence. Catheter ablation reduced symptom burden and complications despite moderate recurrence. Patients wi...
Source: Critical Pathways in Cardiology - May 16, 2020 Category: Cardiology Tags: Review Article Source Type: research

The CHA2DS2-VASc score and Geriatric Multidimensional Assessment tools in elderly patients with persistent atrial fibrillation undergoing electrical cardioversion. A link with arrhythmia relapse?
CONCLUSIONS: The CHA2DS2-VASc score significantly correlated with neuro-cognitive performance, depressive symptoms and physical functioning. It was also associated with AF relapse. Accordingly, in the elderly, the CHA2DS2-VASc could help quantify thrombo-embolic risk, give an indication of frailty status and help to choose between a rate- and a rhythm-control strategy. PMID: 32709545 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - July 21, 2020 Category: Internal Medicine Authors: Fumagalli S, Pelagalli G, Montorzi RF, Marozzi I, Migliorini M, D'Andria MF, Lip GYH, Marchionni N Tags: Eur J Intern Med Source Type: research

Association between use of amiodarone for non-valvular atrial fibrillation and patient survival: from the prospective China Atrial Fibrillation Registry.
CONCLUSIONS: Our study indicated that amiodarone use was not significantly associated with a lower risk of 1-year all-cause mortality compared with a non-AAD strategy in "real-world" patients with NVAF. PMID: 33273373 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - December 1, 2020 Category: General Medicine Authors: Hou XX, He L, Du X, Wang GH, Dong JZ, Ma CS Tags: Chin Med J (Engl) Source Type: research